nach oben

Erschienen in:

01.01.2018 | Respiratory Infections (F Arnold, Section Editor)

Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use

verfasst von: Nicola Principi, Giuseppe Di Cara, Ilaria Bizzarri, Chiara Isidori, Paola Borgia, Costanza Mignini, Marco Saponara, Alberto Argentiero, Susanna Esposito

Erschienen in: Current Infectious Disease Reports | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Starting from 2010, the 13-valent pneumococcal conjugate vaccine (PCV13) was introduced in several countries. This paper discusses some of the problems recently emerged after PCV13 use and their clinical impact. The impact of PCV13 has been relevant and has saved millions of children and adults by severe infectious diseases. However, it seems likely that in the future, effectiveness of the vaccine might be even higher than that presently evidenced. This is because long-term administration of PCV13 to the pediatric population can favor a more extensive reduction of nasopharyngeal colonization with vaccine serotypes of both vaccinated and unvaccinated subjects and further reduce invasive pneumococcal disease in all the individuals (herd immunity). While waiting for new vaccines to be able to overcome the problem of a limited number of pneumococcal strains included in PCV13, it is recommended to increase pneumococcal vaccination coverage in the entire pediatric population.

U.S. Food and Drug Administration. Prevnar 13. Available at: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm. Available at: https://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm. Accessed 4 Sept 2017.

European Medicines Agency. Prevenar 13. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/001104/human_med_001220.jsp&mid=WC0b01ac058001d124. Accessed 4 Sept 2017.

Unicef Supply Division. Pneumococcal conjugate vaccine: Supply and Demand Update. Available at: https://www.unicef.org/supply/files/PCV_Update_Note_July_2014.pdf. Accessed 4 Sept 2017.

Centers for Disease Control and Prevention. Pneumococcal vaccine recommendations. Available at: https://www.cdc.gov/vaccines/vpd/pneumo/hcp/recommendations.html. Accessed 4 Sept 2017.

Weinberger DM, Malley R, Lipsitch M. Serotype replacement in disease after pneumococcal vaccination. Lancet. 2011;378(9807):1962–73. https://doi.org/10.1016/S0140-6736(10)62225-8.CrossRefPubMedPubMedCentral

Esposito S, Principi N. Direct and indirect effects of the 13-valent pneumococcal conjugate vaccine administered to infants and young children. Future Microbiol. 2015;10(10):1599–607. https://doi.org/10.2217/fmb.15.81.CrossRefPubMed

Tomczyk S, Lynfield R, Schaffner W, Reingold A, Miller L, Petit S, et al. Prevention of antibiotic-nonsusceptible invasive pneumococcal disease with the 13-valent pneumococcal conjugate vaccine. Clin Infect Dis. 2016;62(9):1119–25. https://doi.org/10.1093/cid/ciw067.CrossRefPubMed

Geno KA, Gilbert GL, Song JY, Skovsted IC, Klugman KP, Jones C, et al. Pneumococcal capsules and their types: past, present, and future. Clin Microbiol Rev. 2015;28(3):871–99. https://doi.org/10.1128/CMR.00024-15.CrossRefPubMedPubMedCentral

von Gottberg A, de Gouveia L, Tempia S, Quan V, Meiring S, von Mollendorf C, et al. Effects of vaccination on invasive pneumococcal disease in South Africa. N Engl J Med. 2014;371(20):1889–99. https://doi.org/10.1056/NEJMoa1401914.CrossRef

10.

• Shigayeva A, Rudnick W, Green K, Chen DK, Demczuk W, Gold WL, et al. Invasive pneumococcal disease among immunocompromised persons: implications for vaccination programs. Clin Infect Dis. 2016;62(2):139–47. An interesting study showing that PCV13 vaccination of immunocompromised adults may substantially reduce the residual burden until herd immunity from pediatric PCV13 is fully established. https://doi.org/10.1093/cid/civ803.CrossRefPubMed

11.

Waight PA, Andrews NJ, Ladhani SN, Sheppard CL, Slack MP, Miller E. Effect of the 13-valent pneumococcal conjugate vaccine on invasive pneumococcal disease in England and Wales 4 years after its introduction: an observational cohort study. Lancet Infect Dis. 2015;15(5):535–43. https://doi.org/10.1016/S1473-3099(15)70044-7.CrossRefPubMed

12.

Kaplan SL, Barson WJ, Lin PL, Romero JR, Bradley JS, Tan TQ, et al. Early trends for invasive pneumococcal infections in children after the introduction of the 13-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2013;32(3):203–7. https://doi.org/10.1097/INF.0b013e318275614b.CrossRefPubMed

13.

Feikin DR, Kagucia EW, Loo JD, Link-Gelles R, Puhan MA, Cherian T, et al. Serotype-specific changes in invasive pneumococcal disease after pneumococcal conjugate vaccine introduction: a pooled analysis of multiple surveillance sites. PLoS Med. 2013;10(9):e1001517. https://doi.org/10.1371/journal.pmed.1001517.CrossRefPubMedPubMedCentral

14.

Angoulvant F, Levy C, Grimprel E, Varon E, Lorrot M, Biscardi S, et al. Early impact of 13-valent pneumococcal conjugate vaccine on community-acquired pneumonia in children. Clin Infect Dis. 2014;58(7):918–24. https://doi.org/10.1093/cid/ciu006.CrossRefPubMed

15.

Harboe ZB, Dalby T, Weinberger DM, Benfield T, Mølbak K, Slotved HC, et al. Impact of 13-valent pneumococcal conjugate vaccination in invasive pneumococcal disease incidence and mortality. Clin Infect Dis. 2014;59(8):1066–73. https://doi.org/10.1093/cid/ciu524.CrossRefPubMed

16.

Iroh Tam PY, Madoff LC, Coombes B, Pelton SI. Invasive pneumococcal disease after implementation of 13-valent conjugate vaccine. Pediatrics. 2014;134(2):210–7. https://doi.org/10.1542/peds.2014-0473.CrossRefPubMed

17.

Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Lexau C, Bennett NM, et al. Effect of use of 13-valent pneumococcal conjugate vaccine in children on invasive pneumococcal disease in children and adults in the USA: analysis of multisite, population-based surveillance. Lancet Infect Dis. 2015;15(3):301–9. https://doi.org/10.1016/S1473-3099(14)71081-3.CrossRefPubMedPubMedCentral

18.

Simell B, Auranen K, Käyhty H, Goldblatt D, Dagan R, O'Brien KL. The fundamental link between pneumococcal carriage and disease. Expert Rev Vaccines. 2012;11(7):841–55. https://doi.org/10.1586/erv.12.53.CrossRefPubMed

19.

Del Amo E, Esteva C, Hernandez-Bou S, Galles C, Navarro M, Sauca G, et al. Serotypes and clonal diversity of Streptococcus pneumoniae causing invasive disease in the era of PCV13 in Catalonia, Spain. PLoS One. 2016;11:e0151125.CrossRefPubMedPubMedCentral

20.

Muñoz-Almagro C, Esteva C, de Sevilla MF, Selva L, Gene A, Pallares R. Emergence of invasive pneumococcal disease caused by multidrug-resistant serotype 19A among children in Barcelona. J Inf Secur. 2009;59:75–82.

21.

• Moraga-Llop F, Garcia-Garcia JJ, Díaz-Conradi A, Ciruela P, Martínez-Osorio J, González-Peris S, et al. Vaccine failures in patients properly vaccinated with 13-valent pneumococcal conjugate vaccine in Catalonia, a region with low vaccination coverage. Pediatr Infect Dis J. 2016;35(4):460–3. A study showing that 9 patients were considered to have a PCV13 vaccine failure and among these patients serotype 3 was isolated in 6, serotype 19A in 2 and serotype 6B in 1. https://doi.org/10.1097/INF.0000000000001041.CrossRefPubMed

22.

Olarte L, Barson WJ, Bradley JS, Tan TQ, Lin PL, Romero JR, Givner LB, Hoffman JA, Hultén KG, Mason EO, Kaplan SL Invasive pneumococcal disease in infants aged 0-60 days in the United States in the 13-valent pneumococcal conjugate vaccine era. J Pediatric Infect Dis Soc 2017. https://doi.org/10.1093/jpids/pix034.

23.

Centers for Disease Control and Prevention. 2015 Childhood Pneumococcal Conjugate Vaccine (PCV) Coverage Report. Available at: https://www.cdc.gov/vaccines/imz-managers/coverage/childvaxview/data-reports/pcv/reports/2015.html. Accessed 4 Sept 2017.

24.

Gaviria-Agudelo CL, Jordan-Villegas A, Garcia C, McCracken GH Jr. The effect of 13-valent pneumococcal conjugate vaccine on the serotype distribution and antibiotic resistance profiles in children with invasive pneumococcal disease. J Pediatric Infect Dis Soc. 2017;6(3):253–9. https://doi.org/10.1093/jpids/piw005.CrossRefPubMed

25.

•• Esposito S, Colombo C, Tosco A, Montemitro E, Volpi S, Ruggiero L, et al. Streptococcus pneumoniae oropharyngeal colonization in children and adolescents with cystic fibrosis. J Cyst Fibros. 2016;15(3):366–71. A study showing the role of Streptococcus pneumoniae in cystic fibrosis. https://doi.org/10.1016/j.jcf.2015.05.008.CrossRefPubMed

26.

Principi N, Iughetti L, Cappa M, Maffeis C, Chiarelli F, Bona G, et al. Streptococcus pneumoniae oropharyngeal colonization in school-age children and adolescents with type 1 diabetes mellitus: impact of the heptavalent pneumococcal conjugate vaccine. Hum Vaccin Immunother. 2016;12(2):293–300. https://doi.org/10.1080/21645515.2015.1072666.CrossRefPubMed

27.

Esposito S, Terranova L, Patria MF, Marseglia GL, Miraglia del Giudice M, et al. Streptococcus pneumoniae colonisation in children and adolescents with asthma: impact of the heptavalent pneumococcal conjugate vaccine and evaluation of potential effect of thirteen-valent pneumococcal conjugate vaccine. BMC Infect Dis. 2016;16:12.CrossRefPubMedPubMedCentral

28.

Dagan R, Givon-Lavi N, Fraser D, Lipsitch M, Siber GR, Kohberger R. Serum serotype-specific pneumococcal anticapsular immunoglobulin G concentrations after immunization with a 9-valent conjugate pneumococcal vaccine. J Infect Dis. 2005;192(3):367–76. https://doi.org/10.1086/431679.CrossRefPubMed

29.

Pilishvili T, Lexau C, Farley MM, Hadler J, Harrison LH, Bennett NM, et al. Sustained reductions in invasive pneumococcal disease in the era of conjugate vaccine. J Infect Dis. 2010;201(1):32–41. https://doi.org/10.1086/648593.CrossRefPubMed

30.

Tin Tin Htar M, Christopoulou D, Schmitt HJ. Pneumococcal serotype evolution in Western Europe. BMC Infect Dis. 2015;15(1):419. https://doi.org/10.1186/s12879-015-1147-x.CrossRefPubMedPubMedCentral

31.

Chiu C, Dey A, Wang H, Menzies R, Deeks S, Mahajan D, et al. Vaccine preventable diseases in Australia 2005 to 2007. Commun Dis Intell Q Rep. 2010;34(Supp):S1–167.PubMed

32.

•• Moore MR, Link-Gelles R, Schaffner W, Lynfield R, Holtzman C, Harrison LH, et al. Effectiveness of 13-valent pneumococcal conjugate vaccine for prevention of invasive pneumococcal disease in children in the USA: a matched case-control study. Lancet Respir Med. 2016;4(5):399–406. A study showing that PCV13 appears highly effective against invasive pneumococcal disease among children in the USA in the context of routine and catch-up schedules, although some new vaccine antigens could not be assessed. https://doi.org/10.1016/S2213-2600(16)00052-7.CrossRefPubMed

33.

Camilli R, D'Ambrosio F, Del Grosso M, Pimentel de Araujo F, Caporali MG, Del Manso M, et al. Impact of pneumococcal conjugate vaccine (PCV7 and PCV13) on pneumococcal invasive diseases in Italian children and insight into evolution of pneumococcal population structure. Vaccine. 2017;35(35):4587–93. https://doi.org/10.1016/j.vaccine.2017.07.010.CrossRefPubMed

34.

Fry N, Kapatai G, Sheppard C, Litt D, Collins S, Ladhani S, et al. The fall and rise of serotype 19A in invasive pneumococcal disease: application of whole genome sequencing to investigate the recent rise in England and Wales. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016; Glasgow, UK.

35.

Corcoran M, Vickers I, Fitzgerald M, Mereckiene J, Murchan S, Cotter S, et al. The persistence of serotype 19A—despite the introduction of PCV13 vaccine. 10th International Symposium on Pneumococci & Pneumococcal Diseases; 2016; Glasgow, UK.

36.

Desai AP, Sharma D, Crispell EK, Baughman W, Thomas S, Tunali A, et al. Decline in pneumococcal nasopharyngeal carriage of vaccine serotypes after the introduction of the 13-valent pneumococcal conjugate vaccine in children in Atlanta, Georgia. Pediatr Infect Dis J. 2015;34(11):1168–74. https://doi.org/10.1097/INF.0000000000000849.CrossRefPubMed

37.

• Balsells E, Guillot L, Nair H, Kyaw MH. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: a systematic review and meta-analysis. PLoS One. 2017;12(5):e0177113. This study shows the geographic diversity of pneumococcal serotypes and highlights the importance of continued surveillance to guide vaccine design and recommendations. https://doi.org/10.1371/journal.pone.0177113.CrossRefPubMedPubMedCentral

38.

Galanis I, Lindstrand A, Darenberg J, Browall S, Nannapaneni P, Sjöström K, et al. Effects of PCV7 and PCV13 on invasive pneumococcal disease and carriage in Stockholm, Sweden. Eur Respir J. 2016;47(4):1208–18. https://doi.org/10.1183/13993003.01451-2015.CrossRefPubMedPubMedCentral

39.

Lepoutre A, Varon E, Georges S, Dorléans F, Janoir C, Gutmann L, et al. Impact of the pneumococcal conjugate vaccines on invasive pneumococcal disease in France, 2001-2012. Vaccine. 2015;33(2):359–66. https://doi.org/10.1016/j.vaccine.2014.11.011.CrossRefPubMed

40.

Ben-Shimol S, Greenberg D, Givon-Lavi N, Schlesinger Y, Somekh E, Aviner S, et al. Early impact of sequential introduction of 7-valent and 13-valent pneumococcal conjugate vaccine on IPD in Israeli children <5 years: an active prospective nationwide surveillance. Vaccine. 2014;32(27):3452–9. https://doi.org/10.1016/j.vaccine.2014.03.065.CrossRefPubMed

41.

Cooper D, Yu X, Sidhu M, Nahm MH, Fernsten P, Jansen KU. The 13-valent pneumococcal conjugate vaccine (PCV13) elicits crossfunctional opsonophagocytic killing responses in humans to Streptococcus pneumoniae serotypes 6C and 7A. Vaccine. 2011;29(41):7207–11. https://doi.org/10.1016/j.vaccine.2011.06.056.CrossRefPubMedPubMedCentral

42.

Cohen R, Levy C, Bingen E, Koskas M, Nave I, Varon E. Impact of 13-valent pneumococcal conjugate vaccine on pneumococcal nasopharyngeal carriage in children with acute otitis media. Pediatr Infect Dis J. 2012;31(3):297–301. https://doi.org/10.1097/INF.0b013e318247ef84.CrossRefPubMed

43.

Diamantino-Miranda J, Aguiar SI, Carriço JA, Melo-Cristino J, Ramirez M. Clonal and serotype dynamics of serogroup 6 isolates causing invasive pneumococcal disease in Portugal: 1999-2012. PLoS One. 2017;12(2):e0170354. https://doi.org/10.1371/journal.pone.0170354.CrossRefPubMedPubMedCentral

44.

Kalin M. Pneumococcal serotypes and their clinical relevance. Thorax. 1998;53(3):159–62. https://doi.org/10.1136/thx.53.3.159.CrossRefPubMedPubMedCentral

45.

Myint TT, Madhava H, Balmer P, Christopoulou D, Attal S, Menegas D, et al. The impact of 7-valent pneumococcal conjugate vaccine on invasive pneumococcal disease: a literature review. Adv Ther. 2013;30(2):127–51. https://doi.org/10.1007/s12325-013-0007-6.CrossRefPubMed

46.

Fitzwater SP, Chandran A, Santosham M, Johnson HL. The worldwide impact of the seven-valent pneumococcal conjugate vaccine. Pediatr Infect Dis J. 2012;31(5):501–8. https://doi.org/10.1097/INF.0b013e31824de9f6.CrossRefPubMed

47.

• Domínguez Á, Ciruela P, Hernández S, García-García JJ, Soldevila N, Izquierdo C, et al. Effectiveness of the 13-valent pneumococcal conjugate vaccine in preventing invasive pneumococcal disease in children aged 7-59 months. PLoS One. 2017;12(8):e0183191. A study showing the good effectiveness of ≥1 doses of PCV13 in preventing IPD caused by all PCV13 serotypes in children aged 7-59 months. https://doi.org/10.1371/journal.pone.0183191.CrossRefPubMedPubMedCentral

48.

Andrews NJ, Waight PA, Burbidge P, Pearce E, Roalfe L, Zancolli M, et al. Serotype-specific effectiveness and correlates of protection for the 13-valent pneumococcal conjugate vaccine: a postlicensure indirect cohort study. Lancet Infect Dis. 2014;14(9):839–46. https://doi.org/10.1016/S1473-3099(14)70822-9.CrossRefPubMed

49.

Slotved HC, Dalby T, Harboe ZB, Valentiner-Branth P, Casadevante VF, Espenhain L, et al. The incidence of invasive pneumococcal serotype 3 disease in the Danish population is not reduced by PCV-13 vaccination. Heliyon. 2016;2(11):e00198. https://doi.org/10.1016/j.heliyon.2016.e00198.CrossRefPubMedPubMedCentral

50.

Yeh SH, Gurtman A, Hurley DC, Block SL, Schwartz RH, Patterson S, et al. Immunogenicity and safety of 13-valent pneumococcal conjugate vaccine in infants and toddlers. Pediatrics. 2010;126(3):e493–505. https://doi.org/10.1542/peds.2009-3027.CrossRefPubMed

51.

Kieninger DM, Kueper K, Steul K, Kieninger DM, Kueper K, Steul K, et al. Safety, tolerability, and immunologic noninferiority of a 13-valent pneumococcal conjugate vaccine compared to a 7-valent pneumococcal conjugate vaccine given with routine pediatric vaccinations in Germany. Vaccine. 2010;28(25):4192–203. https://doi.org/10.1016/j.vaccine.2010.04.008.CrossRefPubMed

52.

Snape MD, Klinger CL, Daniels ED, John TM, Layton H, Rollinson L, et al. Immunogenicity and reactogenicity of a 13-valent-pneumococcal conjugate vaccine administered at 2, 4, and 12 months of age: a double-blind randomized active-controlled trial. Pediatr Infect Dis J. 2010;29(12):e80–90. https://doi.org/10.1097/INF.0b013e3181faa6be.CrossRefPubMed

53.

Vanderkooi OG, Scheifele DW, Girgenti D, Halperin SA, Patterson SD, Gruber WC, et al. Safety and immunogenicity of a 13-valent pneumococcal conjugate vaccine in healthy infants and toddlers given with routine pediatric vaccinations in Canada. Pediatr Infect Dis J. 2012;31(1):72–7. https://doi.org/10.1097/INF.0b013e318233049d.CrossRefPubMed

54.

Gladstone RA, Jefferies JM, Tocheva AS, Beard KR, Garley D, Chong WW, et al. Five winters of pneumococcal serotype replacement in UK carriage following PCV introduction. Vaccine. 2015;33(17):2015–21. https://doi.org/10.1016/j.vaccine.2015.03.012.CrossRefPubMedPubMedCentral

55.

Varon E, Cohen R, Béchet S, Doit C, Levy C. Invasive disease potential of pneumococci before and after the 13-valent pneumococcal conjugate vaccine implementation in children. Vaccine. 2015;33(46):6178–85. https://doi.org/10.1016/j.vaccine.2015.10.015.CrossRefPubMed

56.

Lindstrand A, Galanis I, Darenberg J, Morfeldt E, Naucler P, Blennow M, et al. Unaltered pneumococcal carriage prevalence due to expansion of non-vaccine types of low invasive potential 8 years after vaccine introduction in Stockholm, Sweden. Vaccine. 2016;34(38):4565–71. https://doi.org/10.1016/j.vaccine.2016.07.031.CrossRefPubMed

57.

• Yildirim I, Little BA, Finkelstein J, Lee G, Hanage WP, Shea K, et al. Surveillance of pneumococcal colonization and invasive pneumococcal disease reveals shift in prevalent carriage serotypes in Massachusetts’ children to relatively low invasiveness. Vaccine. 2017;35(32):4002–9. A study showing that invasive capacity differs among serotypes and likely by age. https://doi.org/10.1016/j.vaccine.2017.05.077.CrossRefPubMed

58.

•• Esposito S, Principi N. Strategies to develop vaccines of pediatric interest. Expert Rev Vaccines. 2017;16(2):175–86. A comprehensive review on vaccines in development. https://doi.org/10.1080/14760584.2017.1237875.CrossRefPubMed

59.

Kaur R, Casey JR, Pichichero ME. Emerging Streptococcus pneumoniae strains colonizing the nasopharynx in children after 13-valent pneumococcal conjugate vaccination in comparison to the 7-valent era, 2006–2015. Pediatr Infect Dis J. 2016;35(8):901–6. https://doi.org/10.1097/INF.0000000000001206.CrossRefPubMedPubMedCentral

60.

Kawaguchiya M, Urushibara N, Kobayashi N. Multidrug resistance in non-PCV13 serotypes of Streptococcus pneumoniae in northern Japan, 2014. Microb Drug Resist. 2017;23(2):206–14. https://doi.org/10.1089/mdr.2016.0054.CrossRefPubMed

61.

McElligott M, Vickers I, Meehan M, Cafferkey M, Cunney R, Humphreys H. Noninvasive pneumococcal clones associated with antimicrobial nonsusceptibility isolated from children in the era of conjugate vaccines. Antimicrob Agents Chemother. 2015;59(9):5761–7. https://doi.org/10.1128/AAC.00990-15.CrossRefPubMedPubMedCentral

62.

Golden AR, Adam HJ, Gilmour MW, Baxter MR, Martin I, Nichol KA, et al. Assessment of multidrug resistance, clonality and virulence in non-PCV-13 Streptococcus pneumoniae serotypes in Canada, 2011-13. J Antimicrob Chemother. 2015;70(7):1960–4. https://doi.org/10.1093/jac/dkv061.PubMed

63.

Olarte L, Kaplan SL, Barson WJ, Romero JR, Lin PL, Tan TQ, et al. Emergence of multidrug-resistant pneumococcal serotype 35B among children in the United States. J Clin Microbiol. 2017;55(3):724–34. https://doi.org/10.1128/JCM.01778-16.CrossRefPubMedPubMedCentral

64.

Mendes RE, Biek D, Critchley IA, Farrell DJ, Sader HS, Jones RN. Decreased ceftriaxone susceptibility in emerging (35B and 6C) and persisting (19A) Streptococcus pneumoniae serotypes in the United States, 2011-2012: ceftaroline remains active in vitro among β-lactam agents. Antimicrob Agents Chemother. 2014;58(8):4923–7. https://doi.org/10.1128/AAC.02976-14.CrossRefPubMedPubMedCentral

65.

Mendes RE, Costello AJ, Jacobs MR, Biek D, Critchley IA, Jones RN. Serotype distribution and antimicrobial susceptibility of USA Streptococcus pneumoniae isolates collected prior to and post introduction of 13-valent pneumococcal conjugate vaccine. Diagn Microbiol Infect Dis. 2014;80(1):19–25. https://doi.org/10.1016/j.diagmicrobio.2014.05.020.CrossRefPubMed

66.

Lee GM, Kleinman K, Pelton SI, Hanage W, Huang SS, Lakoma M, et al. Impact of 13-valent pneumococcal conjugate vaccination on Streptococcus pneumoniae carriage in young children in Massachusetts. Journal of the Pediatric Infectious Diseases Society. 2014;3(1):23–3287. https://doi.org/10.1093/jpids/pit057.CrossRefPubMed

67.

Metcalf BJ, Gertz RE Jr, Gladstone RA, Walker H, Sherwood LK, Jackson D, et al. Strain features and distributions in pneumococci from children with invasive disease before and after 13-valent conjugate vaccine implementation in the USA. Clin Microbiol Infect. 2016;22(1):60.e9–60. https://doi.org/10.1016/j.cmi.2015.08.027.CrossRef

68.

Kim L, McGee L, Tomczyk S, Beall B. Biological and epidemiological features of antibiotic-resistant Streptococcus pneumoniae in pre- and post-conjugate vaccine eras: a United States perspective. Clin Microbiol Rev. 2016;29(3):525–52. https://doi.org/10.1128/CMR.00058-15.CrossRefPubMedPubMedCentral

69.

Camilli R, Daprai L, Cavrini F, Lombardo D, D'Ambrosio F, Del Grosso M, et al. Pneumococcal carriage in young children one year after introduction of the 13-valent conjugate vaccine in Italy. PLoS One. 2013;8(10):e76309. https://doi.org/10.1371/journal.pone.0076309.CrossRefPubMedPubMedCentral

70.

Van Hoek AJ, Sheppard CL, Andrews NJ, Waight PA, Slack MPE, Harrison TG, et al. Pneumococcal carriage in children and adults two years after introduction of the thirteen valent pneumococcal conjugate vaccine in England. Vaccine. 2014;32(34):4349–55. https://doi.org/10.1016/j.vaccine.2014.03.017.CrossRefPubMed

Titel: Prevention of Invasive Pneumococcal Disease: Problems Emerged After Some Years of the 13-Valent Pneumococcal Conjugate Vaccine Use
verfasst von: Nicola Principi
Giuseppe Di Cara
Ilaria Bizzarri
Chiara Isidori
Paola Borgia
Costanza Mignini
Marco Saponara
Alberto Argentiero
Susanna Esposito
Publikationsdatum: 01.01.2018
Verlag: Springer US
Erschienen in: Current Infectious Disease Reports / Ausgabe 1/2018
Print ISSN: 1523-3847
Elektronische ISSN: 1534-3146
DOI: https://doi.org/10.1007/s11908-018-0607-z

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen